NAGE Chromadex Corp: רווח למניה ב-12 החודשים האחרונים

Chromadex Corp maintains its leadership in biosynthesis due to exclusive patents for Niagen. The relative EPS YoY TTM growth rate visualizes profit dynamics, where -50.40 serves as the current metric level. However, reliance on a single product, Tru Niagen, creates risks that the company mitigates through licensing. Meanwhile, innovations in cellular energy metabolism are shifting nutraceuticals into the realm of evidence-based medicine.
פילוחי מדדים פיננסיים ומדדי שוק עבור Chromadex Corp (NAGE)

This metric measures the annual dynamics of earnings per share, comparing current 10-K and 10-Q reporting data with the market price to identify hidden yield imbalances. By analyzing the rolling year YoY EPS growth chart, an investor can assess how effectively the commercialization of Niagen and the demand for Chromadex Corp (NAGE) biochemical supplements convert into real growth in shareholder value.